MCID: PRX034
MIFTS: 39

Peroxisome Disorders malady

Categories: Rare diseases

Aliases & Classifications for Peroxisome Disorders

Aliases & Descriptions for Peroxisome Disorders:

Name: Peroxisome Disorders 50
Peroxisomal Disorders 52 69
Disorder of Peroxisomal Function 50
Peroxisomal Disease 50
Peroxisomal Defects 50
Peroxisome Diseases 50

Classifications:



Summaries for Peroxisome Disorders

MalaCards based summary : Peroxisome Disorders, also known as peroxisomal disorders, is related to peroxisomal disease and adrenoleukodystrophy. An important gene associated with Peroxisome Disorders is GNPAT (Glyceronephosphate O-Acyltransferase), and among its related pathways/superpathways are Metabolism and Peroxisome. The drugs Pioglitazone and Nitric Oxide have been mentioned in the context of this disorder. Affiliated tissues include liver and skin, and related phenotypes are homeostasis/metabolism and growth/size/body region

Related Diseases for Peroxisome Disorders

Diseases related to Peroxisome Disorders via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 58)
id Related Disease Score Top Affiliating Genes
1 peroxisomal disease 11.5
2 adrenoleukodystrophy 11.0
3 refsum disease 11.0
4 peroxisome biogenesis disorder 1a 10.9
5 peroxisome biogenesis disorder 14b 10.8
6 alpha-methylacyl-coa racemase deficiency 10.8
7 d-bifunctional protein deficiency 10.8
8 peroxisomal fatty acyl-coa reductase 1 disorder 10.8
9 peroxisome biogenesis disorder 6a 10.6
10 peroxisome biogenesis disorder 13a 10.6
11 acatalasemia 10.6
12 peroxisome biogenesis disorder 8a, 10.6
13 peroxisome biogenesis disorder 12a 10.6
14 peroxisome biogenesis disorder 2a 10.6
15 chondrodysplasia punctata, rhizomelic, type 2 10.6
16 peroxisome biogenesis disorder 3a 10.6
17 peroxisome biogenesis disorder 11a 10.6
18 chondrodysplasia punctata, rhizomelic, type 3 10.6
19 peroxisome biogenesis disorder 7a 10.6
20 peroxisome biogenesis disorder 4a 10.6
21 chondrodysplasia punctata, rhizomelic, type 1 10.6
22 peroxisome biogenesis disorder 9b 10.6
23 peroxisome biogenesis disorder 10a 10.6
24 peroxisome biogenesis disorder 5a 10.6
25 inflammatory bowel disease 18 10.1 HSD17B4 PHYH
26 spinocerebellar ataxia, autosomal recessive 13 10.1 HADHB HSD17B4 PEX7
27 pulmonary fibrosis, familial 10.1 PEX1 PEX2 PEX5
28 doughnut lesions of skull, familial 10.1 GNPAT PEX5 PEX7
29 zellweger syndrome 10.1
30 bardet-biedl syndrome 5 10.0 AGPS GNPAT PEX5 PEX7
31 agammaglobulinemia, non-bruton type 10.0 ABCD1 SLC25A17
32 holoprosencephaly 6 10.0 AGPS GNPAT PEX5 PEX7
33 short-rib thoracic dysplasia 13 with or without polydactyly 10.0 HADHB HSD17B4
34 growth hormone deficiency, isolated, type ii 10.0 PEX1 PEX5 PEX7 TRIM37
35 sclerosing keratitis 9.9 ABCD1 PEX5 SLC25A17
36 macroglobulinemia 9.9 AGPS GNPAT PEX1 PEX2 PEX5
37 rhizomelic chondrodysplasia punctata 9.9
38 deafness, dystonia, and cerebral hypomyelination 9.8 ABCD1 CAT PEX1 PEX5
39 glottis neoplasm 9.8 AGPS GNPAT HADHB PEX5 PEX7 PHYH
40 muscular dystrophy, congenital, 1b 9.8 AGPS CAT GNPAT PEX5 PEX7
41 mental retardation, autosomal recessive 44 9.8 AGXT CAT HSD17B4 PEX5
42 parapsoriasis 9.7 ABCD1 GNPAT HADHB HSD17B4 PEX2 PEX5
43 heimler syndrome 1 9.7 CAT GNPAT HSD17B4 PEX1 PEX2 PEX5
44 neonatal adrenoleukodystrophy 9.7
45 mulibrey nanism 9.7
46 phacomatosis pigmentokeratotica 9.6 ABCD1 CAT HSD17B4 PEX1 PEX2 PEX5
47 diabetes, mellitus, insulin-dependent 10 9.5 CAT GNPAT HADHB PEX1 PEX2 PEX5
48 peroxisomal biogenesis disorders 9.5
49 intellectual disability 9.5
50 child syndrome 9.5

Graphical network of the top 20 diseases related to Peroxisome Disorders:



Diseases related to Peroxisome Disorders

Symptoms & Phenotypes for Peroxisome Disorders

MGI Mouse Phenotypes related to Peroxisome Disorders:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 PEX1 PEX11B PEX2 PEX5 PEX7 PHYH
2 growth/size/body region MP:0005378 10.07 PEX1 PEX11B PEX2 PEX5 PEX7 PHYH
3 endocrine/exocrine gland MP:0005379 10.01 ABCD1 AGPS GNPAT HSD17B4 PEX2 PEX5
4 liver/biliary system MP:0005370 9.91 HADHB HSD17B4 PEX1 PEX11B PEX2 PEX5
5 mortality/aging MP:0010768 9.9 AGPS CAT GNPAT HADHB HSD17B4 PEX1
6 nervous system MP:0003631 9.65 ABCD1 GNPAT HSD17B4 PEX1 PEX11B PEX2
7 reproductive system MP:0005389 9.23 GNPAT HSD17B4 PEX5 PEX7 PHYH TRIM37

Drugs & Therapeutics for Peroxisome Disorders

Drugs for Peroxisome Disorders (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 195)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 111025-46-8 4829
2
Nitric Oxide Approved Phase 4 10102-43-9 145068
3
Fenofibrate Approved Phase 4,Phase 2 49562-28-9 3339
4
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
5
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
6
Ramipril Approved Phase 4 87333-19-5 5362129
7
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
8
Telmisartan Approved, Investigational Phase 4,Phase 2 144701-48-4 65999
9
Bisoprolol Approved Phase 4 66722-44-9 2405
10
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
11
Glimepiride Approved Phase 4 93479-97-1 3476
12
Angiotensin II Phase 4,Phase 2 68521-88-0, 11128-99-7 65143 172198
13 insulin Phase 4,Phase 3,Phase 2
14 Analgesics Phase 4,Phase 1,Phase 2,Early Phase 1
15 Cyclooxygenase Inhibitors Phase 4,Early Phase 1
16 Analgesics, Non-Narcotic Phase 4,Early Phase 1
17 Hormone Antagonists Phase 4,Phase 3,Early Phase 1
18 Hormones Phase 4,Phase 3,Early Phase 1
19 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2,Early Phase 1
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Early Phase 1
21 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 2
22 Angiotensin Receptor Antagonists Phase 4,Phase 2
23 Angiotensinogen Phase 4,Phase 2
24 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1
25 2,4-thiazolidinedione Phase 4,Phase 2
26 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2
27 Anti-Inflammatory Agents Phase 4,Phase 1,Early Phase 1
28 Antihypertensive Agents Phase 4,Phase 2
29 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Early Phase 1
30 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 isosorbide-5-mononitrate Phase 4
32 Rosuvastatin Calcium Phase 4 147098-20-2
33 diuretics Phase 4
34
protease inhibitors Phase 4,Phase 3
35 Adrenergic Agents Phase 4
36 Natriuretic Agents Phase 4
37 Adrenergic Antagonists Phase 4
38 Sitagliptin Phosphate Phase 4,Phase 3
39 Adrenergic beta-1 Receptor Antagonists Phase 4
40 Neurotransmitter Agents Phase 4,Phase 1,Phase 2
41 Adrenergic beta-Antagonists Phase 4
42 Sympatholytics Phase 4
43 HIV Protease Inhibitors Phase 4,Phase 3
44 Nitric Oxide Donors Phase 4
45 Dipeptidyl-Peptidase IV Inhibitors Phase 4,Phase 3
46 Vasodilator Agents Phase 4,Phase 3
47 Angiotensin-Converting Enzyme Inhibitors Phase 4
48 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
49 Hypolipidemic Agents Phase 4,Phase 3,Phase 2
50 Platelet Aggregation Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 116)
id Name Status NCT ID Phase
1 Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone. Completed NCT00449553 Phase 4
2 Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects Completed NCT01589445 Phase 4
3 Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients Completed NCT00745225 Phase 4
4 Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease Completed NCT03011775 Phase 4
5 The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome Completed NCT00926341 Phase 4
6 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4
7 Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes Completed NCT00599885 Phase 4
8 The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans Completed NCT00872599 Phase 4
9 A Portion-controlled Diet Will Prevent Weight Gain in Diabetics Treated With ACTOS Completed NCT00219440 Phase 4
10 Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy Recruiting NCT02338921 Phase 4
11 Rosiglitazone Plaque Study Unknown status NCT00123227 Phase 3
12 Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid Completed NCT00007020 Phase 3
13 Betaine and Peroxisome Biogenesis Disorders Completed NCT01838941 Phase 3
14 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3
15 PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease Completed NCT00554853 Phase 3
16 Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery Disease Completed NCT01574820 Phase 3
17 Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept Completed NCT00811681 Phase 3
18 Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes Completed NCT01156597 Phase 3
19 Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052) Completed NCT00350779 Phase 3
20 A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD) Recruiting NCT01896102 Phase 2, Phase 3
21 MD1003-AMN MD1003 in Adrenomyeloneuropathy Active, not recruiting NCT02961803 Phase 2, Phase 3
22 Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy Suspended NCT00004418 Phase 2, Phase 3
23 A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy Terminated NCT00545597 Phase 3
24 ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases Terminated NCT00654433 Phase 3
25 Endometriosis: Immunomodulation Withdrawn NCT01184144 Phase 2, Phase 3
26 Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis Withdrawn NCT00121953 Phase 2, Phase 3
27 HSCT for High Risk Inherited Inborn Errors Completed NCT00383448 Phase 2
28 A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants Completed NCT01495260 Phase 2
29 Canakinumab in Patients With Active Hyper-IgD Syndrome Completed NCT01303380 Phase 2
30 Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia Completed NCT00006493 Phase 2
31 Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2 Completed NCT02278562 Phase 2
32 Substrate Cycling in Energy Metabolism Completed NCT00361751 Phase 2
33 Troglitazone in Treating Patients With Liposarcoma Completed NCT00003058 Phase 2
34 Telmisartan Versus Losartan in Kidney Transplantation Completed NCT01224860 Phase 2
35 Pioglitazone for Heroin and for Nicotine Dependence Completed NCT01395797 Phase 1, Phase 2
36 Treating Nonalcoholic Steatohepatitis With Pioglitazone Completed NCT00062764 Phase 2
37 Treatment of Nonalcoholic Steatohepatitis With Pioglitazone Completed NCT00013598 Phase 2
38 A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism Completed NCT00327002 Phase 2
39 Study to Evaluate the Safety and Analgesic Activity of ATx08-001 in Subjects With Postherpetic Neuralgia Completed NCT01318226 Phase 2
40 A Clinical Trial to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia Completed NCT01539616 Phase 2
41 Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects Completed NCT02444910 Phase 2
42 A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator Completed NCT00631007 Phase 2
43 Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes Completed NCT00575471 Phase 2
44 Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes Completed NCT00575874 Phase 2
45 A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma Completed NCT00994175 Phase 2
46 MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Recruiting NCT02171104 Phase 2
47 A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy Recruiting NCT02595489 Phase 1, Phase 2
48 Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy Recruiting NCT02559830 Phase 1, Phase 2
49 Phase 2b Study in NASH to Assess IVA337 Recruiting NCT03008070 Phase 2
50 Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery Recruiting NCT02249949 Phase 2

Search NIH Clinical Center for Peroxisome Disorders

Genetic Tests for Peroxisome Disorders

Anatomical Context for Peroxisome Disorders

MalaCards organs/tissues related to Peroxisome Disorders:

39
Liver, Skin

Publications for Peroxisome Disorders

Articles related to Peroxisome Disorders:

(show top 50) (show all 55)
id Title Authors Year
1
Safety of long-term restrictive diets for peroxisomal disorders: vitamin and trace element status of patients treated for Adult Refsum Disease. ( 26799636 )
2016
2
A peroxisomal disorder of severe intellectual disability, epilepsy, and cataracts due to fatty acyl-CoA reductase 1 deficiency. ( 25439727 )
2014
3
Defective lipid remodeling of GPI anchors in peroxisomal disorders, Zellweger syndrome, and rhizomelic chondrodysplasia punctata. ( 22253471 )
2012
4
Phytanic acid and pristanic acid, branched-chain fatty acids associated with Refsum disease and other inherited peroxisomal disorders, mediate intracellular Ca2+ signaling through activation of free fatty acid receptor GPR40. ( 21570468 )
2011
5
Visual follow-up in peroxisomal-disorder patients treated with docosahexaenoic Acid ethyl ester. ( 19933185 )
2010
6
Investigational methods for peroxisomal disorders. ( 18633975 )
2008
7
Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review. ( 17956237 )
2007
8
High incidence of hyperoxaluria in generalized peroxisomal disorders. ( 16621644 )
2006
9
Combined liquid chromatography-tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders: preliminary findings. ( 16828324 )
2006
10
Peroxisomal disorders I: biochemistry and genetics of peroxisome biogenesis disorders. ( 15679822 )
2005
11
Metabolic and molecular basis of peroxisomal disorders: a review. ( 15098234 )
2004
12
Mulibrey nanism--a novel peroxisomal disorder. ( 14713209 )
2003
13
Stereochemistry of the peroxisomal branched-chain fatty acid alpha- and beta-oxidation systems in patients suffering from different peroxisomal disorders. ( 11893780 )
2002
14
Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. ( 11948235 )
2002
15
The TRIM37 gene encodes a peroxisomal RING-B-box-coiled-coil protein: classification of mulibrey nanism as a new peroxisomal disorder. ( 11938494 )
2002
16
The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder. ( 10088993 )
1999
17
Immunological analyses of alkyl-dihydroxyacetone-phosphate synthase in human peroxisomal disorders. ( 10384985 )
1999
18
Stability of alkyl-dihydroxyacetonephosphate synthase in human control and peroxisomal disorder fibroblasts. ( 10683770 )
1999
19
X-linked dominant chondrodysplasia punctata: a peroxisomal disorder? ( 9677071 )
1998
20
Developmental delay and growth failure caused by a peroxisomal disorder, dihydroxyacetonephosphate acyltransferase (DHAP-AT) deficiency. ( 9843043 )
1998
21
[Molecular analysis of peroxisomal disorders]. ( 9545777 )
1998
22
Cholesterol biosynthesis, peroxisomes and peroxisomal disorders: mevalonate kinase is not only deficient in Zellweger syndrome but also in rhizomelic chondrodysplasia punctata. ( 9686383 )
1998
23
New insights in peroxisomal beta-oxidation. Implications for human peroxisomal disorders. ( 9803880 )
1998
24
Characterization of phytanoyl-Coenzyme A hydroxylase in human liver and activity measurements in patients with peroxisomal disorders. ( 9565335 )
1998
25
Immunological localization and tissue distribution of alkyldihydroxyacetonephosphate synthase and deficiency of the enzyme in peroxisomal disorders. ( 9266692 )
1997
26
On the molecular etiology of decreased arachidonic (20:4n-6), docosapentaenoic (22:5n-6) and docosahexaenoic (22:6n-3) acids in Zellweger syndrome and other peroxisomal disorders. ( 9062899 )
1997
27
D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase bifunctional protein deficiency: a newly identified peroxisomal disorder. ( 9345094 )
1997
28
Peroxisomal disorders: clinical aspects. ( 8993563 )
1996
29
Infantile Refsum disease: neonatal cholestatic jaundice presentation of a peroxisomal disorder. ( 7533834 )
1995
30
Rhizomelic chondrodysplasia punctata: report of a case with review of the literature and correlation with other peroxisomal disorders. ( 8597837 )
1995
31
Human peroxisomal targeting signal-1 receptor restores peroxisomal protein import in cells from patients with fatal peroxisomal disorders. ( 7790377 )
1995
32
Immunolocalization of a 43 kDa peroxisomal membrane protein in the liver of patients with generalized peroxisomal disorders. ( 8521871 )
1995
33
Peroxisome disorders and cutaneous manifestations. ( 8305747 )
1994
34
A new type of peroxisomal disorder with variable expression in liver and fibroblasts. ( 7931872 )
1994
35
Human alkyldihydroxyacetonephosphate synthase deficiency: a new peroxisomal disorder. ( 7807941 )
1994
36
Prenatal diagnosis of peroxisomal disorders. Biochemical and immunocytochemical studies on peroxisomes in human amniocytes. ( 8059925 )
1994
37
Lactic acidosis and mitochondrial dysfunction in two children with peroxisomal disorders. ( 8105143 )
1993
38
Peroxisomal disorders in children: immunohistochemistry and neuropathology. ( 8463903 )
1993
39
Infantile refsum disease: gastrointestinal presentation of a peroxisomal disorder. ( 1374125 )
1992
40
Peroxisomal abnormality in fibroblasts from involved skin of CHILD syndrome. Case study and review of peroxisomal disorders in relation to skin disease. ( 1519936 )
1992
41
Bifunctional enzyme deficiency: identification of a new type of peroxisomal disorder in a patient with an impairment in peroxisomal beta-oxidation of unknown aetiology by means of complementation analysis. ( 1357231 )
1992
42
Fatty acid composition of human myelin proteolipid protein in peroxisomal disorders. ( 1704424 )
1991
43
Very large peroxisomes in distinct peroxisomal disorders (rhizomelic chondrodysplasia punctata and acyl-CoA oxidase deficiency): novel data. ( 1750197 )
1991
44
Pathology of hepatic peroxisomes and mitochondria in patients with peroxisomal disorders. ( 1689088 )
1990
45
Analysis of very long-chain fatty acids and plasmalogen in the erythrocyte membrane: a simple method for the detection of peroxisomal disorders and discrimination between adrenoleukodystrophy and Zellweger syndrome. ( 2234315 )
1990
46
Genetic relationship between the Zellweger syndrome and other peroxisomal disorders characterized by an impairment in the assembly of peroxisomes. ( 2183242 )
1990
47
Mitochondrial oxidation of phytanic acid in human and monkey liver: implication that Refsum's disease is not a peroxisomal disorder. ( 1690986 )
1990
48
A new peroxisomal disorder with enlarged peroxisomes and a specific deficiency of acyl-CoA oxidase (pseudo-neonatal adrenoleukodystrophy). ( 2894756 )
1988
49
Molecular analysis of peroxisomal beta-oxidation enzymes in infants with Zellweger syndrome and Zellweger-like syndrome: further heterogeneity of the peroxisomal disorder. ( 2452040 )
1988
50
The cerebro-hepato-renal (Zellweger) syndrome and other peroxisomal disorders. ( 3319743 )
1987

Variations for Peroxisome Disorders

Expression for Peroxisome Disorders

Search GEO for disease gene expression data for Peroxisome Disorders.

Pathways for Peroxisome Disorders

GO Terms for Peroxisome Disorders

Cellular components related to Peroxisome Disorders according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 peroxisome GO:0005777 9.8 ABCD1 AGPS AGXT CAT GNPAT HSD17B4
2 peroxisomal matrix GO:0005782 9.7 AGPS AGXT CAT GNPAT HSD17B4 PEX7
3 integral component of peroxisomal membrane GO:0005779 9.56 ABCD1 PEX11B PEX2 SLC25A17
4 peroxisomal membrane GO:0005778 9.32 ABCD1 AGPS CAT GNPAT HSD17B4 PEX1
5 mitochondrion GO:0005739 10.06 ABCD1 AGPS AGXT CAT GNPAT HADHB

Biological processes related to Peroxisome Disorders according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 fatty acid metabolic process GO:0006631 9.67 HADHB HSD17B4 PHYH
2 response to fatty acid GO:0070542 9.48 CAT GNPAT
3 fatty acid beta-oxidation using acyl-CoA oxidase GO:0033540 9.46 ABCD1 HSD17B4
4 protein import into peroxisome matrix GO:0016558 9.46 PEX1 PEX2 PEX5 PEX7
5 alpha-linolenic acid metabolic process GO:0036109 9.43 ABCD1 HSD17B4
6 ether lipid biosynthetic process GO:0008611 9.43 AGPS GNPAT PEX7
7 peroxisome organization GO:0007031 9.43 ABCD1 PEX1 PEX11B PEX2 PEX5 PEX7
8 very long-chain fatty acid metabolic process GO:0000038 9.4 HSD17B4 PEX2
9 protein targeting to peroxisome GO:0006625 9.37 PEX1 PEX7
10 fatty acid alpha-oxidation GO:0001561 9.32 PHYH SLC25A17
11 fatty acid beta-oxidation GO:0006635 9.17 ABCD1 HADHB HSD17B4 PEX2 PEX5 PEX7

Molecular functions related to Peroxisome Disorders according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.56 AGXT CAT GNPAT HSD17B4
2 enzyme binding GO:0019899 9.46 ABCD1 CAT PEX5 PEX7
3 protein homodimerization activity GO:0042803 9.17 ABCD1 AGXT CAT HSD17B4 PEX11B PEX7
4 3-hydroxyacyl-CoA dehydrogenase activity GO:0003857 8.96 HADHB HSD17B4

Sources for Peroxisome Disorders

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....